GlassScriptPhysician profile
Tarek Amoun
NPI 1487176327
$7,230.42
in general payments reported to CMS, 2019-2025
27 companies · $808 in 2025
The $808 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $56.29 · 2022: $28.19 · 2023: $3,745 · 2024: $2,594 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,557 · Food and Beverage: $2,351 · Travel and Lodging: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,557.48 |
| Food and Beverage | $2,350.60 |
| Travel and Lodging | $237.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,841.33 | 2023-2024 | Ion, Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $643.51 | 2023-2025 | Airsupra, Andexxa, Breztri |
| Glaxosmithkline, LLC. | $306.30 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $156.32 | 2023-2025 | Winrevair, Keytruda |
| Regeneron Healthcare Solutions, INC. | $126.33 | 2023-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $120.35 | 2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.58 | 2022-2025 | Ofev |
| Genzyme Corporation | $95.20 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $80.71 | 2024-2025 | Opsumit, Uptravi |
| Amgen INC. | $80.09 | 2024-2025 | Tezspire |
| Cmp Pharma, INC. | $66.91 | 2023 | Tadliq, Norliqva, Liqrev |
| Axsome Therapeutics, INC. | $58.83 | 2023-2024 | Sunosi |
| Sanofi-Aventis U.S. LLC | $57.48 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.88 | 2024-2025 | Glassia |
| Harmony Biosciences LLC | $53.67 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $40.53 | 2024 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $37.70 | 2023-2025 | |
| Mylan Specialty L.P. | $37.70 | 2023-2024 | Yupelri |
| Vifor Pharma, INC. | $37.30 | 2024 | Zemaira, Veltassa |
| Johnson & Johnson Health Care Systems INC. | $30.75 | 2023 | Opsumit |
| Stryker Corporation | $27.58 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Verona Pharma, INC. | $27.33 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $23.35 | 2024 | |
| Ani Pharmaceuticals, INC. | $17.42 | 2025 | Purified Cortrophin Gel |
| Avadel Cns Pharmaceuticals, LLC | $16.74 | 2024 | Lumryz |
| Philips North America LLC | $14.63 | 2022 | |
| Medtronic, INC. | $14.61 | 2024 | Illumisite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarek Amoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.